ReviewFrontiers in oncology2018
Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and Meta-Analysis.International journal of urology : official journal of the Japanese Urological Association · 2025Pooled it
- Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.BMC cancer · 2021Pooled it
- Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.Frontiers in oncology · 2021Pooled it
- An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery.International journal of radiation oncology, biology, physics · 2026Article
- Outcomes of Management of Progressive Radiosurgery-Treated Brain Metastasis With Resection Followed by Pathology-Informed Management: A Retrospective Study.Neurosurgery practice · 2024Article
- Article
- Multi-institutional study of 'Sandwich treatment' for motor area large brain metastases (LBM) with diameter over 3 cm.Radiology and oncology · 2024Article
- KRASOncoTargets and therapy · 2024Review
- Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.Journal of neuro-oncology · 2023Article
- Article
- The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases.Frontiers in oncology · 2023Review
- CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations.Frontiers in oncology · 2023Article
- Dosimetric impact of mechanical movements of the Linac gantry during treatments with small fields.Frontiers in oncology · 2022Article
- Article
- The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes.Journal of neuro-oncology · 2021Article
- Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?Translational lung cancer research · 2021Review
- Intracranial long-term complications of radiation therapy: an image-based review.Neuroradiology · 2021Review
- Radiation Necrosis in Intracranial Lesions.Cureus · 2020Review
- Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis.Neuro-oncology practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the prognosis of metastatic non-small cell lung cancer (NSCLC) patients is constantly improving with advances in systemic therapies (immune checkpoint blockers and new generation of targeted molecular compounds), more attention should be paid to the diagnosis and management of treatments-related long-term secondary effects. Brain metastases (BM) occur frequently in the natural history of NSCLC and stereotactic radiation therapy (SRT) is one of the main efficient local non-invasive therapeutic methods. However, SRT may have some disabling side effects. Brain radiation necrosis (RN) represents one of the main limiting toxicities, generally occurring from 6 months to several years after treatment. The diagnosis of RN itself may be quite challenging, as conventional imaging is frequently not able to differentiate RN from BM recurrence. Retrospective studies have suggested increased incidence rates of RN in NSCLC patients with oncogenic driver mutations [epidermal growth factor receptor (EGFR) mutated or anaplastic lymphoma kinase (ALK) positive] or receiving tyrosine kinase inhibitors. The risk of immune checkpoint inhibitors in contributing to RN remains controversial. Treatment modalities for RN have not been prospectively compared. Those include surveillance, corticosteroids, bevacizumab and local interventions (minimally invasive laser interstitial thermal ablation or surgery). The aim of this review is to describe and discuss possible RN management options in the light of the newly available literature, with a particular focus on NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.